Research programme: DNA vaccines - CytoGenix
Alternative Names: CYDBA 507; Ebola virus DNA vaccine - CytoGenix; H5N1 influenza virus vaccine - CytoGenix; HIV DNA vaccine - CytoGenix; Influenza A virus DNA vaccine H5N1 - CytoGenix; Multivalent DNA vaccine against H5N1 - CytoGenix; Pandemic flu DNA vaccine - CytoGenix; Seasonal flu DNA vaccine - CytoGenix; Smallpox DNA vaccine - CytoGenixLatest Information Update: 04 Nov 2017
At a glance
- Originator CytoGenix
- Developer CytoGenix; United States Army Medical Research Institute of Infectious Diseases
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ebola virus infections; HIV infections; Influenza A virus H5N1 subtype; Influenza virus infections; Smallpox
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Ebola-virus-infections(Prevention) in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (Parenteral)